- Home
- GMAB vs DOW Comparison
GMAB vs DOW Comparison
Compare GMAB & DOW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- DOW
- Stock Information
- Founded
- GMAB 1999
- DOW 1897
- Country
- GMAB Denmark
- DOW United States
- Employees
- GMAB N/A
- DOW N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- DOW Major Chemicals
- Sector
- GMAB Health Care
- DOW Industrials
- Exchange
- GMAB Nasdaq
- DOW Nasdaq
- Market Cap
- GMAB 17.4B
- DOW 16.3B
- IPO Year
- GMAB N/A
- DOW N/A
- Fundamental
- Price
- GMAB $30.42
- DOW $22.95
- Analyst Decision
- GMAB Strong Buy
- DOW Hold
- Analyst Count
- GMAB 6
- DOW 15
- Target Price
- GMAB $40.40
- DOW $27.13
- AVG Volume (30 Days)
- GMAB 2.4M
- DOW 13.9M
- Earning Date
- GMAB 11-06-2025
- DOW 10-23-2025
- Dividend Yield
- GMAB N/A
- DOW 6.11%
- EPS Growth
- GMAB 132.41
- DOW N/A
- EPS
- GMAB 25.10
- DOW N/A
- Revenue
- GMAB $3,845,670,022.00
- DOW $40,913,000,000.00
- Revenue This Year
- GMAB $24.92
- DOW N/A
- Revenue Next Year
- GMAB $15.97
- DOW $2.54
- P/E Ratio
- GMAB $11.82
- DOW N/A
- Revenue Growth
- GMAB 29.57
- DOW N/A
- 52 Week Low
- GMAB $17.24
- DOW $20.40
- 52 Week High
- GMAB $33.65
- DOW $46.35
- Technical
- Relative Strength Index (RSI)
- GMAB 56.40
- DOW 49.85
- Support Level
- GMAB $28.08
- DOW $22.07
- Resistance Level
- GMAB $30.78
- DOW $22.75
- Average True Range (ATR)
- GMAB 0.68
- DOW 0.70
- MACD
- GMAB 0.10
- DOW -0.06
- Stochastic Oscillator
- GMAB 84.63
- DOW 32.03
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About DOW Dow Inc.
Dow Chemical is a diversified global chemicals producer, formed in 2019 as a result of the DowDuPont merger and subsequent separations. The firm is a leading producer of several chemicals, including polyethylene, ethylene oxide, and silicone rubber. Its products have numerous applications in both consumer and industrial end markets.